Semaglutide vs Tirzepatide: 2026 Head-to-Head

· clinical-corner · 9 min read

Mechanism, weight loss, A1C, cardiovascular and kidney outcomes, dosing structure, supply, pricing dynamics — a clean 2026 side-by-side for the two molecules that defined the incretin era.

Semaglutide and tirzepatide are the two molecules that defined the modern incretin era. Semaglutide is a pure GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. As of mid-2026, both have multiple FDA approvals, both have read out on cardiovascular and renal endpoints, and both are increasingly competing on the same indications. This is a clean side-by-side for researchers and clinicians.

Mechanism at a glance

Both compounds act on incretin receptors that mediate post-prandial insulin release, gastric emptying, and central appetite signaling. Tirzepatide adds GIP receptor agonism on top of GLP-1, which appears to amplify weight loss and metabolic benefit relative to GLP-1 alone. See our semaglutide profile and tirzepatide profile for sequence-level detail.

Mechanism and pharmacology comparison
PropertySemaglutideTirzepatide
ClassGLP-1 RAGIP/GLP-1 dual RA
ManufacturerNovo NordiskEli Lilly
Approved asOzempic, Wegovy, RybelsusMounjaro, Zepbound
RouteSC weekly, oral daily (Rybelsus)SC weekly
Half-life~7 days~5 days
First FDA approval2017 (Ozempic, T2D)2022 (Mounjaro, T2D)

Weight loss and A1C

The clearest head-to-head dataset is SURMOUNT-5, a 72-week randomized trial that compared maximum-tolerated tirzepatide versus maximum-tolerated semaglutide in adults with obesity. Tirzepatide produced more weight loss and more responders at the ≥15% threshold. For dosing structure, see our tirzepatide reconstitution calculator and semaglutide reconstitution calculator.

Headline efficacy comparison (approximate, study-dependent)
EndpointSemaglutide 2.4 mgTirzepatide 15 mg
Mean weight loss at ~72 weeks~15%~21%
≥15% weight loss responders~50%~70%
A1C reduction (T2D, head-to-head SURPASS-2)~1.8%~2.3%
Direct head-to-head (obesity, SURMOUNT-5)Reference armStatistically superior
Cardiovascular outcomes confirmedYes (SUSTAIN-6, SELECT)SURPASS-CVOT readout pending

Beyond glucose and weight: outcomes data

Both molecules now have data well beyond their original indications. SELECT (semaglutide) established MACE reduction in non-diabetic patients with established CV disease. SUMMIT (tirzepatide) showed benefit in HFpEF with obesity. SYNERGY-NASH (tirzepatide) and ESSENCE (semaglutide) addressed MASH. FLOW (semaglutide) showed renal benefit in T2D with CKD. See our clinical trials tracker for the full readout calendar.

Confirmed outcomes coverage as of mid-2026
IndicationSemaglutideTirzepatide
Type 2 diabetesApprovedApproved
Chronic weight managementApprovedApproved
MACE reduction in CVD + obesityApproved (SELECT)Pending (SURPASS-CVOT)
Heart failure (HFpEF + obesity)STEP-HFpEF (positive)SUMMIT (positive)
MASHESSENCE (positive Ph3)SYNERGY-NASH (positive Ph2)
CKD in T2DFLOW (positive)Not yet
Obstructive sleep apnea + obesityNot yetSURMOUNT-OSA (approved indication)
Alzheimer's diseaseEVOKE / EVOKE+ ongoingNot yet

Tolerability and discontinuation

Both classes share the same dominant side-effect profile: nausea, vomiting, constipation, and early-treatment GI distress that improves with slow titration. Discontinuation rates in trials are broadly similar across the two molecules; real-world adherence is shaped more by titration support and supply than by inherent tolerability differences.

Supply, price, and access in 2026

Both molecules came off the FDA drug-shortage list. Compounded semaglutide and tirzepatide have been pushed out of the legal U.S. supply for most patients except where a personalized clinical need is documented. List prices remain high in the U.S.; international markets vary widely. See the regulation tracker for ongoing updates.

U.S. market posture (mid-2026)
FactorSemaglutide (Novo)Tirzepatide (Lilly)
FDA shortage list statusResolvedResolved
Legal 503A compoundingRestrictedRestricted
Direct-to-patient programNovoCareLillyDirect
Generic timeline (U.S.)Late 2030s (patents)Late 2030s (patents)
Pipeline successorCagriSema, oral semaglutide 25/50 mgRetatrutide, orforglipron

What comes next

For the full pipeline tracker, see our pharma desk and the semaglutide vs tirzepatide vs retatrutide long-form guide.